Yale Cancer Center at 2015 ASCO Annual Meeting

Clinical Science Symposiums:Saturday, May 30; 9:03 AM - 9:15 AMLocation: E Hall D1Immunotherapy for Every Patient: Check Your EnthusiasmRoy S. Herbst, MD, PhD Monday, June 1; 3:48 PM - 4:00 PMLocation: E Arie Crown TheaterChimeric Antigen Receptor T-Cell Therapy for B-Cell MalignanciesMadhav V. Dhodapkar, MBBS Oral Abstract Sessions: Saturday, May 30; 4:36 PM - 4:48 PMLocation: E Hall D1Small Cell Lung Cancer: A Glimpse of LightRoy S. Herbst, MD, PhD Monday, June 1; 9:48 AM - 10:00 AMLocation: S102Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women's Activity and Lifestyle Study in Connecticut (WALC).Yang Zhou, MD, MPH Monday, June 1; 10:24 AM - 10:36 AMLocation: S102Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors.Melinda L. Irwin, PhD, MPH Monday, June 1; 12:09 PM - 12:21 PMLocation: E450The Potential Role of Allogeneic Stem Cell Transplantation in Peripheral T-Cell LymphomaFrancine M. Foss, MD Monday, June 1; 9:57 AM - 10:09 AMLocation: E Arie Crown TheaterA phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).Daniel P. Petrylak, MD

First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.|2015 ASCO Annual Meeting AbstractsDaniel P. Petrylak, MD

Monday, June 1; 3:15 PM - 3:27 PMLocation: S100bcHPV and Epstein-Barr Virus-Related Head and Neck Cancer: Deintensification and SurveillanceBarbara Burtness, MD Poster Discussion Session:Saturday, May 30; 3:00 PM - 3:12 PM/ Discussing Abstracts: 3009, 3010, 3011, 3012Location: S406Expanding Indications of Checkpoint BlockadeHarriet Kluger, MD Poster Sessions: S Hall ASaturday, May 30; 8:00 AM - 11:30 AMProspective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.Tara Sanft, MD A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.Maysa Abu-Khalaf, MD A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).Maysa Abu-Khalaf, MD Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.Mehmet Altan, MD

Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.Sarah Schellhorn Mougalian, MD Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Kurt Alex Schalper, MD/PhD Poster Sessions: S Hall ASaturday, May 30; 1:15 PM - 4:45 PMDistress in cancer survivors attending a multidisciplinary survivorship clinic.Tara Sanft, MD Trends and regional variation of end-of-life cancer care in the Medicare program.Shi-Yi Wang, MD, PhD Contemporary national trends of prostate cancer screening among privately insured patients in the United States.Simon P. Kim, MD, MPH Poster Sessions: S Hall A2Monday, June 1; 8:00 AM - 11:30 AMFirst-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.Scott Gettinger, MD Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.Sarah Goldberg, MD "The burden upon me": The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.Carolyn Jean Presley, MD Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer.Elyn H. Wang, BS Clinical diagnostic utility of a blood-based multi-transcriptome assay for gastroenteropancreatic disease.Irvin Mark Modlin, MD, PhD Poster Sessions: S Hall AMonday, June 1; 1:15 PM - 4:45 PMA framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).Anton Safonov, BS

Education Sessions:Saturday, May 30; 1:15 PM - 1:35 PMLocation: E Hall D1Recent Positive Clinical Trials and Data in Context of Study Results, Design, and EndpointsRogerio Lilenbaum, MD Tuesday, June 2; 11:45 AM - 12:00 PMLocation: E450Lung CancerRogerio Lilenbaum, MD